Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 104Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 41Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Irinotecan 21Capecitabine 19Leucovorin 18Fulvestrant 18Cetuximab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fluorouracil 17Docetaxel 17Bevacizumab 17Drug Therapy 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Indomethacin × 1 year × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡